Trissel Lawrence A, Zhang Yanping, Xu Quanyun A
Clinical Pharmaceutics Research Division, Division of Pharmacy, The University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Int J Pharm Compd. 2002 Mar-Apr;6(2):155-7.
The objective of this study was to evaluate the chemical stability of 4-aminopyridine 5-mg capsules and 3,4-diaminopyridine 5-mg capsules under a variety of storage conditions. Each of the two drug preparations was extemporaneously prepared in hard gelatin capsules; lactose and micronized silica gel were used as excipients. Samples were stored under three conditions: refigeration at 4 deg C and protected from light for 6 months, protected from light at room temperature that ranged from 22 deg C to 24 deg C for 6 months, and at a temperature of 37 deg C and protected from light for 1 month. Once each month, visual inspection of the capsules and their powder contents was performed to identify observable changes (color, texture, etc) and the weight of the capsule content was measured individually. Chemical stability was assessed initially and at monthly intervals by means of a stability-indicating high-pressure liquid chromatography (HPLC) analytical technique based on the determination of drug content. No visible changes were observed in any of the samples under any of the storage conditions. The hard gelatin capsules remained clear and colorless, and the content of the capsules remained an off-white powder when viewed under normal fluorescent room light. Capsule content weight did not change during the study. Both 4-aminopyridine and 3,4-diaminopyridine exhibited excellent chemical stability under all study conditions. Little or no loss of drug content occurred in either product under refrigeration, at room temperature, and even at the elevated temperature of 37 deg C. The oral 5-mg capsules of 4-aminopyridine and 3,4 diaminopyridine did not undergo decomposition or other adverse changes within 6 months at refrigerated room temperature or within 1 month of storage at 37 deg C.
本研究的目的是评估5毫克4-氨基吡啶胶囊和5毫克3,4-二氨基吡啶胶囊在各种储存条件下的化学稳定性。两种药物制剂均临时装入硬明胶胶囊中;乳糖和微粉硅胶用作辅料。样品在三种条件下储存:4℃冷藏并避光保存6个月,22℃至24℃室温下避光保存6个月,37℃温度下避光保存1个月。每月进行一次,对胶囊及其粉末内容物进行目视检查,以识别可观察到的变化(颜色、质地等),并分别测量胶囊内容物的重量。最初以及每隔一个月通过基于药物含量测定的稳定性指示高压液相色谱(HPLC)分析技术评估化学稳定性。在任何储存条件下,任何样品均未观察到明显变化。在正常室内荧光灯下观察,硬明胶胶囊保持清澈无色,胶囊内容物仍为灰白色粉末。在研究期间,胶囊内容物重量未发生变化。在所有研究条件下,4-氨基吡啶和3,4-二氨基吡啶均表现出优异的化学稳定性。在冷藏、室温甚至37℃高温下,两种产品的药物含量均很少或没有损失。4-氨基吡啶和3,4-二氨基吡啶的口服5毫克胶囊在冷藏室温下6个月内或在37℃储存1个月内均未发生分解或其他不良变化。